Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237536 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Threshold Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00237536: Clinical Trial Phase 2 study, sponsored by Threshold Pharmaceuticals.
NCT00237536 is a Phase 2 study that was terminated before completion, run by Threshold Pharmaceuticals. The registered enrollment target is 240 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00237536, a Phase 2 study, was terminated before completion, sponsored by Threshold Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
Interventions
- DRUG Lonidamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Why NCT00237536 stopped before completion
NCT00237536 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 1 intervention - of which Lonidamine is the first listed.
NCT00237536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00237536 about?
NCT00237536 is a clinical study titled "Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia". The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
What is the current status of trial NCT00237536?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2005-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00237536?
The interventions under investigation include: Lonidamine (DRUG).
Who is sponsoring clinical trial NCT00237536?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00237536's enrollment target sits among peer trials
240 239th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia